目的 探討香連化滯丸聯(lián)合美沙拉嗪治療潰瘍性結(jié)腸炎的臨床療效。方法 納入駐馬店市中醫(yī)院于2020年1月—2021年6月收治的98例潰瘍性結(jié)腸炎患者為研究對(duì)象，隨機(jī)分為對(duì)照組和治療組，每組各49例。對(duì)照組患者口服美沙拉嗪腸溶片，1 g/次，4次/d，治療組在對(duì)照組的基礎(chǔ)口服香連化滯丸，12 g/次，2次/d。兩組均治療12周。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀緩解時(shí)間，二胺氧化酶、D-乳酸、超氧化物歧化酶、丙二醛、轉(zhuǎn)化生長因子-β（TGF-β）、白細(xì)胞介素-10（IL-10）和IL-17水平。結(jié)果 治療后，對(duì)照組和治療組總有效率分別為81.63%、95.92%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，與對(duì)照組相比，治療組血便消失平均時(shí)間及腹瀉次數(shù)至少降低50%所需時(shí)間顯著縮短（P<0.05）。治療后，兩組二胺氧化酶、D-乳酸、丙二醛和IL-17水平均顯著降低，超氧化物歧化酶、TGF-β和IL-10水平顯著升高（P<0.05），且治療組這些指標(biāo)顯著好于對(duì)照組（P<0.05）。結(jié)論 香連化滯丸聯(lián)合美沙拉嗪治療潰瘍性結(jié)腸炎臨床療效顯著，能顯著改善潰瘍性結(jié)腸炎患者的腸道黏膜屏障功能、氧化應(yīng)激水平及Th17/Treg細(xì)胞失衡。

Objective To investigate the clinical efficacy of Xianglian Huazhi Pills combined with mesalazine in treatment of ulcerative colitis. Methods 98 Patients with ulcerative colitis admitted to Zhumadian TCM Hospital from January 2020 to June 2021 were included and randomly divided into control and treatment group, and each group had 49 cases. Patients in the control group were po administered with Mesalazin Enteric-coated Tablets, 1 g/time, four times daily. Patients in the treatment group were po administered with Xianglian Huazhi Pills on the basis of the control group, 12 g/time, twicece daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical evaluation was evaluated, the remission time of clinical symptoms, the levels of diamine oxidase, D-lactic acid, superoxide dismutase, malondialdehyde, TGF-β, IL-10, and IL-17 in two groups before and after treatment were compared. Results After treatment, the clinical effective rates of the control group and the treatment group were 81.63% and 95.92% respectively, and there was significant difference between the two groups (P < 0.05). After treatment, compared with the control group, the average time of disappearance of bloody stool and the number of diarrhea were significantly shortened by at least 50% (P < 0.05) in the treatment group. After treatment, the levels of diamine oxidase, D-lactic acid, malondialdehyde, and IL-17 were significantly decreased, while the levels of superoxide dismutase, TGF-β, and IL-10 were significantly increased in two groups(P < 0.05), and these indexes in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion The clinical effect of Xianglian Huazhi Pills combined with mesalazine in treatment of ulcerative colitis is remarkable, can significantly improve intestinal mucosal barrier function, oxidative stress level and Th17/Treg cell imbalance in patients with ulcerative colitis.

R975